COVID-19 Information Center
- Coronavirus disease
COVID-19 Information Center
Novartis is responding to the coronavirus disease (COVID-19) with safety of associates and patients globally as our primary concern. We are also contributing to research efforts, supporting communities and ensuring stable supply and price of essential medicines. This information center provides a central hub for updates, guidance and other resources.
Novartis response to COVID-19
In the face of a global crisis, Novartis has quickly mobilized R&D capabilities, medicines, clinical trials expertise and philanthropic aid to address the coronavirus disease pandemic.
NIBR Science of Therapeutics Symposium: Coronavirus Antivirals
Join us for a ‘hard core’ science event focused on finding therapeutic solutions to this ongoing health crisis.
Novartis signs initial agreement to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient for Roche’s Actemra/RoActemra®
Molecular Partners and Novartis report positive initial results from Phase 1 study of COVID-19 antiviral therapy
Novartis signs initial agreement to provide manufacturing capacity for CureVac COVID-19 vaccine candidate
The agreement will see Novartis utilizing its new high-tech production facilities in Kundl, Austria.
Novartis signs initial agreement to provide manufacturing capacity for Pfizer-BioNTech COVID-19 vaccine
The agreement will see Novartis utilizing its aseptic manufacturing facilities at its site in Stein, Switzerland.
Update on Novartis RUXCOVID trial
The RUXCOVID clinical trial highlights the Novartis commitment to leverage our expertise and resources to support the global response to the COVID-19 pandemic.
Novartis COVID-19 Response Fund
The fund, launched in March 2020, has supported public health initiatives to help communities manage challenges posed by COVID-19.
Monocle’s The Big Interview Podcast
Monocle’s editorial director, Tyler Brûlé, is joined by Vas Narasimhan, CEO of Swiss pharmaceutical giant Novartis.
COVID one year on: Learning the lessons for sustainable patient access
CEO of Sandoz, Richard Saynor, reflects on the past year and on-going efforts to maintain overall manufacturing and supply security for essential medicines.
Novartis helps COVID-19 vaccine supply
A conversation with Joachim Momm, head of a Novartis manufacturing site that will be helping to produce Pfizer-BioNTech vaccine doses.
Containing COVID-19 to serve patient needs
The coronavirus crisis has not only challenged the medical community to seek new treatments and vaccines. Keeping up with the production of existing drugs is equally challenging. Novartis has taken a series of measures to maintain production levels and serve millions of patients.
Novartis COVID-19 Stories
Read how Novartis is approaching the pandemic through the eyes of its associates.
Novartis COVID-19 Response Fund
Novartis COVID-19 Response Fund is providing urgently-needed support for healthcare workers and communities in over 50 projects around the world.
